In August 2026, Alvotech announced a licensing and commercialization agreement with Lotus Pharmaceutical for biosimilar candidates AVT34 (Imfinzi) and AVT87 (Hemlibra) across the United States and eight Asian markets, with potential consideration of up to approximately US$150 million plus ongoing supply revenues.
The deal expands Alvotech's access to oncology and hematology markets while keeping it in control of development, regulatory approvals, and global product supply.
We'll now examine how this expanded US and Asian commercialization footprint for AVT34 and AVT87 could influence Alvotech's broader investment narrative.
The future of work is here. Discover the 38 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
To own Alvotech, you have to believe its expanding biosimilar portfolio and partnerships can convert into steadier revenues despite regulatory and pricing uncertainty. The Lotus deal for AVT34 and AVT87 broadens Alvotech's reach in oncology and hematology and could modestly support near term milestones, but it does not change that the key short term catalyst remains timely FDA and EMA decisions on late stage assets, while the biggest risk is still revenue lumpiness tied to approvals and milestones.
The most directly relevant recent announcement is Alvotech's 2026 revenue guidance of US$650 million to US$700 million, issued just before the Lotus agreement. That target already relies heavily on product and milestone flows, so any upfront or milestone payments from Lotus, if realized, would sit inside an already ambitious framework. Against this, the recent swing back to a net loss in the first half of 2026 underlines how dependent the company still is on the timing of approvals and partner ramp up.
Yet behind the expansion with Lotus, investors should be aware that delays to key FDA or EMA decisions could still...
Read the full narrative on Alvotech (it's free!)
Alvotech's narrative projects $1.0 billion revenue and $242.3 million earnings by 2029.
Uncover how Alvotech's forecasts yield a $5.75 fair value, a 16% upside to its current price.
Some of the lowest ranked analysts were already cautious, assuming revenue of about US$982.5 million and earnings of roughly US$82.7 million by 2029, so this partnership and the timing of regulatory milestones could meaningfully shift how you weigh that more pessimistic view against the baseline story.
Explore 5 other fair value estimates on Alvotech - why the stock might be worth 19% less than the current price!
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
A great starting point for your Alvotech research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
Our free Alvotech research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Alvotech's overall financial health at a glance.
Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:
Find 44 companies with promising cash flow potential yet trading below their fair value.
AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
Rare earth metals are the new gold rush. Find out which 30 stocks are leading the charge.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ALVO.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]